The study by Kohlmeyer and Lingo et al. [105] revealed a high potential for MEK–CDK4/6 inhibitor therapy, especially when combined with immunotherapy, to induce sustained tumor regression and better survival in MPNST patients. The gene discussed is MAP2K7; the disease is neoplasm.